Chronic Lymphocytic Leukemia: An Update on Current Treatment Approaches

References

• Galton, D. A. G. (1966). The pathogenesis of chronic lymphocytic leukemia. Can. Med. Assoc. J., 94, 1005–10.
   PubMed Web of Science ®Google Scholar
• Dameshek, W. (1967). Chronic lymphocytic leukemia—an accumulative disease of immunologically incompetent lymphocytes. Blood, 29, 566–84.
   PubMed Web of Science ®Google Scholar
• Rozman, C. (editor). (1993). Chronic lymphocytic leukaemia and related disorders. Bailliére's Clinical Haematology, 6, 757–919.
   Google Scholar
• Gale, R. P., Caligaris-Cappio, F. and Dighiero, G. et al. (International Workshop on CLL). (1994). Recent progress in chronic lymphocytic leukemia. Leukemia, 8, 1610–4.
   PubMed Web of Science ®Google Scholar
• Cheson, B. D. (1994). Chronic lymphocytic leukemia and hairy-cell leukemia. Current Opinion Haematology, 1, 268–77 & B91–B93.
   PubMedGoogle Scholar
• Montserrat, E. and Rozman, C. (1995). Chronic lymphocytic leukemia: Present status. Ann. Oncol., 6, 219–35.
   PubMed Web of Science ®Google Scholar
• O'Brien, S., del Giglio, A., Keating, M. J. (1995). Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood, 85, 307–18.
   PubMed Web of Science ®Google Scholar
• Rozman, C. and Montserrat, E. (1995). Chronic lymphocytic leukemia. N. Engl. J. Med., 333, 1052–7.
   PubMed Web of Science ®Google Scholar
• Cheson, B. D., Bennet, J. M., Rai, K. R. et al. (1988). Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. Am. J. Hematol., 29, 152–63.
   PubMed Web of Science ®Google Scholar
• International Workshop on CLL. (1989). Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann. Int. Med., 110, 236–8.
   PubMed Web of Science ®Google Scholar
• Matutes, E., Owusu-Ankomah, K., Morilla, R. et al. (1994). The immunologic profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia, 8, 1640–5.
   PubMed Web of Science ®Google Scholar
• Bennet, J. M., Catovsky, D., Daniel, M. T. et al. (1989). Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J. Clin. Pathol., 42, 567–84.
   PubMed Web of Science ®Google Scholar
• Litz, G. E. and Brunning, R. D. (1993). Chronic lymphoproliferative disorders: classification and diagnosis. Bailliére's Clin. Haematol., 6, 767–83.
   PubMedGoogle Scholar
• Mulligan, S. and Catovsky, D. (1991). Splenic lymphoma with villous lymphocytes. Leuk. Lymphoma., 6, 97–105.
   Web of Science ®Google Scholar
• Pangalis, G. A., Boussiotis, V. A. and Kittas, C. (1993). Malignant disorders of small lymphocytes. Am. J. Clin. Pathol., 99, 402–8.
   PubMed Web of Science ®Google Scholar
• Raffeld, M., Sander, C. A., Yano, T. and Jaffe, E. S. (1992). Mantle cell lymphoma: An update. Leuk. Lymphoma., 8, 161–6.
   PubMed Web of Science ®Google Scholar
• Rai, K. R., Sawitsky, A., Cronkite, E. P. et al. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219–34.
   PubMed Web of Science ®Google Scholar
• Binet, J. L., Auqier, A., Dighiero, G. et al. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198–206.
   PubMed Web of Science ®Google Scholar
• International Workshop on CLL (1981). Chronic lymphocytic leukaemia: proposals for a revised prognostic staging system. Br. J. Haematol., 48, 365–7.
   PubMed Web of Science ®Google Scholar
• Rozman, C., Montserrat, E., Rodríguez-Fernández, J. M. et al. (1984). Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood, 64, 642–8.
   PubMed Web of Science ®Google Scholar
• Geisler, C., Ralfkiaer, E., Hansen, M. M. et al. (1986). The bone marrow histological pattern has independent prognostic value in early stage chronic lymphocytic leukemia. Br. J. Haematol., 62, 47–54.
   PubMed Web of Science ®Google Scholar
• Montserrat, E., Villamor, N., Reverter, J. C. et al. (1996). Bone marrow assessment in B-cell chronic lymphocytic leukaemia: aspirate or biopsy?. A comparative study in 258 patients. Br. J. Haematol., 93, 111–6.
   PubMed Web of Science ®Google Scholar
• Rozman, C., Montserrat, E., Feliu, E. et al. (1982). Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases. Blood, 59, 1001–5.
   PubMed Web of Science ®Google Scholar
• Montserrat, E., Sánchez-Bisonó J, Viñolas, N. et al. (1986). Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br. J. Haematol., 62, 567–75.
   PubMed Web of Science ®Google Scholar
• Vallespí, T., Montserrat, E., Sanz, M. A. (1991). Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A. multivariate analysis in 146 patients. Br. J. Haematol., 77, 478–85.
   PubMed Web of Science ®Google Scholar
• Juliusson, G., Gahrton, G. (1993). Cytogenetics in CLL and related disorders. Bailliére's Clin. Haematol., 6, 821–48.
   PubMed Web of Science ®Google Scholar
• Montserrat, E., Gomis, F., Vallespí, T. et al. (1991). Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood, 78, 1545–51.
   PubMed Web of Science ®Google Scholar
• Lee, J. S., Dixon, D. O., Kantarjian, H. M. et al. (1987). Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood, 69, 929–36.
   PubMed Web of Science ®Google Scholar
• Ellims, P. H., Gan, T. E., van der Weyden, M. B. (1981). Thymidine kinase isoenzymes in chronic lymphocytic leukaemia. Br. J. Haematol., 49, 479–85.
   PubMed Web of Science ®Google Scholar
• Reinisch., Willheim, M., Hilgarth, M. et al. (1994). Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J. Clin. Oncol., 12, 2146–52.
   PubMed Web of Science ®Google Scholar
• Keating, M. J., Lerner, S., Kantarjian, H. et al. (1995). The serum B2-microglobulin (B2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) (abstract). Blood, 86, 606a.
   Web of Science ®Google Scholar
• Montserrat, E., Viñolas, N., Reverter, J. C. et al. (1988). Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early clinical stages. Nouv. Rev. Fraç Hematol., 30, 359–61.
   PubMedGoogle Scholar
• Montserrat, E. and Rozman, C. (1993). Chronic lymphocytic leukaemia treatment. Blood Reviews, 7, 164–75.
   PubMed Web of Science ®Google Scholar
• Shustik, C., Mick, R., Silver, R., Sawitsky, A., Rai, K. and Shapiro, L. (1988). Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hematol. Oncoli., 6, 7–12.
   PubMed Web of Science ®Google Scholar
• French Cooperative Group on Chronic Lymphocytic Leukemia (1990). Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood, 75, 1414–21.
   PubMed Web of Science ®Google Scholar
• Catovsky, D., Richards, S., Fooks, J. et al. (MRC Working Party on Leukaemia in Adults) (1991). CLL trials in the United Kingdom. Leuk. Lymphoma., 5 (suppl), 105–12.
   PubMed Web of Science ®Google Scholar
• Spanish Cooperative Group PETHEMA (1991). Treatment of chronic lymphocytic leukemia: Preliminary report of Spanish (PETHEMA) trials. Leuk. Lymphoma., 5, 89–91.
   PubMed Web of Science ®Google Scholar
• Brugiatelli, M., Jaksic, B., Planic-Peraica, A. et al. (1995). Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: Long-term results of a randomized trial. Eur. J. Haematol., 55, 158–63.
   PubMed Web of Science ®Google Scholar
• Montserrat, E., Alcalá, A., Alonso, C. et al. (1988). A randomized trial comparing chlorambucil plus prednisone vs. cyclophosphamide., melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. N. Rev. Franç Hematol, 30, 429–32.
   PubMed Web of Science ®Google Scholar
• Hansen, M. M., Andersen, E., Birgens, H. et al. (1991). CHOP versus chlorambucil plus prednisolone in chronic lymphocytic leukemia. Leuk Lymphoma, 5 (suppl), 97–100.
   PubMed Web of Science ®Google Scholar
• Kimby, E. and Mellstedt, H. (1991). Chlorambucil/Prednisone versus CHOP in symptomatic chronic lymphocytic leukemia of B-cell type. A. randomized trial. Leuk Lymphoma, 5 (suppl), 93–6.
   PubMed Web of Science ®Google Scholar
• Montserrat, E., Alcaiá, A., Parody, R. et al. (1985). Treatment of chronic lymphocytic leukemia in advanced stage: a randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer, 56, 2369–75.
   PubMed Web of Science ®Google Scholar
• Raphael, B., Andersen, J. W., Silber, R. et al. (1991). Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J. Clin. Oncol, 9, 770–6.
   PubMed Web of Science ®Google Scholar
• O'Brien, S., Kantarjian, H., Beran, M. et al. (1993). Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood, 82, 1695–1700.
   PubMed Web of Science ®Google Scholar
• Keating, M. J., O'Brien, S., Kantarjian, H. et al. (1993). Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood, 81, 2878–84.
   PubMed Web of Science ®Google Scholar
• Tallman, M. S. and Hakimian, D. (1995). Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood, 86, 2463–74.
   PubMed Web of Science ®Google Scholar
• Montserrat, E., López-Lorenzo, J. L., Manso, F. et al. (1996). Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia. Leuk. Lymphoma., 21, 467–72.
   PubMed Web of Science ®Google Scholar
• The French Cooperative Group on CLL et al. (1996). Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet, in press.
   Google Scholar
• Aabo, K. and Walbom-Jorgensen, S. (1985). Spleen irradiation in chronic lymphocytic leukemia (CLL): palliation in patients unfit for splenectomy. Am. J. Hematol., 19, 177–80.
   PubMed Web of Science ®Google Scholar
• Chikappa, G., Pasquale, D., Zarrabi, M. H., Weiler, R. J., Divakara, M. and Tsan, M. F. (1992). Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am. J. Hematol., 41, 5–12.
   PubMed Web of Science ®Google Scholar
• Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia (1988). Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A. randomized controlled clinical trial. N. Engl. J. Med., 319, 902–7.
   PubMed Web of Science ®Google Scholar
• Boughton, B. J., Jackson, N., Lim, S. and Smith, N. (1995). Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin. Lab. Haem., 17, 75–80.
   PubMedGoogle Scholar
• Weeks, J. C., Tierney, M. R. and Weinstein, M. C. (1991). Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N. Engl. J. Med., 325, 81–6.
   PubMed Web of Science ®Google Scholar
• Chapel, H., Dicato, M. H. Gamm, H. et al. (1994). Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimens. Br. J. Haematol, 88, 209–12.
   PubMed Web of Science ®Google Scholar
• Jurlander, J., Hartmann, Geisler, C. and Hansen, M. M. (1994). Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur. J. Haematol., 53, 114–8.
   PubMed Web of Science ®Google Scholar
• Hollander, A. A. M. J., Kluin-Nelemans, H. C., Haak, H. R. et al. (1991). Correction of neutropenia associated with chronic lymphocytic leukemia following treatment with granulocyte-macrophage colony-stimulating factor. Ann Hematol, 62, 32–4.
   PubMed Web of Science ®Google Scholar
• Pangalis, G. A., Poziopoulos, Ch., Angelopoulo, M. K., Siankantaris, M. P. and Panayiotidis, P. (1995). Effective treatment of anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br. J. Haematol., 89, 627–9.
   PubMed Web of Science ®Google Scholar
• Saven, A., Lemon, R. H., Kosty, M., Beutler, E. and Piro, L. D. (1995). 2-chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol., 13, 570–4.
   PubMed Web of Science ®Google Scholar
• Delannoy, A., Martiat, P, Gala, J. L. et al. (1995). 2-chlorodeoxyadenosine (CdA) for patients with previously untreated chronie-lymphocytic leukemia (CLL). Leukemia, 9, 1130–5.
   PubMed Web of Science ®Google Scholar
• Rai, K. R., Peterson, B., Kolitz, J. et al. (1995). Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). A randomized inter-group study (abstract). Blood, 86 (suppl 1), 607a.
   PubMed Web of Science ®Google Scholar
• Cheson, B. D. (1995). Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol., 13, 2431–48.
   PubMed Web of Science ®Google Scholar
• Di Raimondo, F., Giustolisi, R., Cacciola, E., O'Brien, S., Kantarjian, H., Robertson, L. B. and Keating, M. J. (1993). Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk. Lymphoma., 11, 63–8.
   PubMed Web of Science ®Google Scholar
• Myint, H., Copplestone, A., Orchad, J. et al. (1995). Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br. J. Haematol., 91, 341–4.
   PubMed Web of Science ®Google Scholar
• Frame, J. N., Dahut, W. L. and Crowley, S. (1992). Fludarabine and acute tumor lysis syndrome in chronic lymphocytic leukemia (letter). N. Engl. J. Med., 5, 1396.
   Google Scholar
• Stickney, D. R. and Foon, K. A. (1992). Biologic response modifiers: therapeutic approaches to lymphoproliferative diseases. Current Opin. Oncol., 4, 847–55.
   PubMedGoogle Scholar
• Grossbard, M. L., Press, O. W., Appelbaum, F. R. et al. (1992). Monoclonal antibody-based therapies for leukemia and lymphoma. Blood, 80, 863–78.
   PubMed Web of Science ®Google Scholar
• Rabinowe, S. N., Grossbard, M. L., Nadler, L. M. (1993). Innovative treatment strategies for chronic lymphocytic leukemia: monoclonal antibodies, immunoconjugates, and bone marrow transplantation. In “Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments“, edited by B. D. Cheson, pp. 337–67. New York, Marcel Dekker Inc.
   Google Scholar
• Levy, R. (1993). Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature, 362, 755–8.
   PubMed Web of Science ®Google Scholar
• Montserrat, E., Villamor, N., Urbano-Ispizua, A. et al. (1991). Alpha interferon in chronic lymphocytic leukaemia. Eur. J. Cancer., 27 (suppl 4), 74–7.
   PubMed Web of Science ®Google Scholar
• O'Brien, S., Kantarjian, H., Beran, M., Robertson, L. E., Koller, C. and Keating, M. J. (1995). Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood, 86, 1296–1300.
   Web of Science ®Google Scholar
• Zinzani, P. L., Levrero, M. G., Lauria, F. et al. (1994). Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Haematologica, 79, 55–60.
   PubMed Web of Science ®Google Scholar
• LeMaistre, C. F., Meneghetti, C., Rosenblum, M. et al. (1992). Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood, 79, 2547–54.
   PubMed Web of Science ®Google Scholar
• Peng, B., Mehta, N. H., Fernandes, H., Chou, C. C. and Raveché, E. (1995). Growth inhibition of malignant CD5 + B (B - 1) cells by antisense IL-10 oligonucleotide. Leuk. Res., 19, 159–67.
   PubMed Web of Science ®Google Scholar
• Michallet, M., Archimbaud, E., Bandini, G. et al. (1996). HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann. Intern. Med., 124, 311–5.
   PubMed Web of Science ®Google Scholar
• Michallet, M., Archimbaud, E., Rowlings, P. A., Horowitz, M. M., Apperley, J., Gratwhol, A. and Gale, R. P. (1996). Hematopoietic stem cell transplant for chronic lymphocytic leukemia (abstract). Bone Marrow Transpl., 17, (suppl 1), S3.
   Google Scholar
• Rabinowe, S. N., Soiffer, R.J., Gribben, J. G. et al. (1993). Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood, 82, 1366–76.
   PubMed Web of Science ®Google Scholar
• Khouri, I. F., Keating, M. J., Vriesendorp, H. M. et al. (1994). Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J. Clin. Oncol., 12, 748–58.
   PubMed Web of Science ®Google Scholar
• Sadoun, A., Patri, S., Delwail, V. et al. (1994). Molecular remission after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transpl., 13, 217–9.
   PubMed Web of Science ®Google Scholar